Study Shows MRI Can Detect Breast Disease Missed by Mammography

News
Article
OncologyONCOLOGY Vol 20 No 4
Volume 20
Issue 4

Researchers have found that mammography coupled with magnetic resonance imaging (MRI) is extremely sensitive in the detection of ductal carcinoma in situ (DCIS).

Researchers have found that mammography coupled with magnetic resonance imaging (MRI) is extremely sensitive in the detection of ductal carcinoma in situ (DCIS). The recent study, which was published in The Breast Journal (11[6]:382-390, 2005), examined the medical records of women diagnosed with DCIS, aged 34 to 79 years, who underwent MRI and mammographic examinations over approximately 2 years.

The results revealed 39 sites of pure DCIS in 33 breasts of 32 women. In each of these women, both MRI and mammograms were performed prior to surgery. Of the 33 breasts involved, DCIS was detected by MRI alone in 64%, and detected by mammography alone in only 3%. MRI and mammography together detected DCIS in 24% of breasts; in 9%, DCIS was found at mastectomy but the mammogram and MRI were negative. The nuclear grade of DCIS detected by MRI and mammography was similar, although the size of lesions identified by MRI was larger. Breast density did not affect the results.

Recommendations

"The results from our small, select group of patients suggest that in women with known or suspected DCIS, determination of the presence and extent of disease may be best established with mammography complemented by MRI," concluded the researchers, led by Jennifer Menell, md, Memorial Sloan-Kettering Cancer Center.

The American Cancer Society recommends that women age 40 and older should have a mammogram every year and that those at increased risk should talk with their doctors about the benefits and limitations of starting mammograms when they are younger, having additional tests (such as MRI), or having more frequent exams.

Recent Videos
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Physical therapists may play a key role in patient care before, during, and after treatment for cancer, according to Alison Ankiewicz, PT, DPT.
Recommending counseling sessions may help patients with cancer navigate sexual health and emotional issues during their cancer treatment.
Beyond DNA-centric diagnostics, protein-based methods may play a role in accurately matching patients with the most effective therapies.
Related Content